Table 1

Characteristics of the studies included in the indirect treatment comparison model

Non-PSP group (BPAP study)18PSP group (VOICE study)17
Data sourceUK, retrospective cohort study based on data collected as part of routine patient care during the benralizumab patient access programmeUK, retrospective cohort study based on data collected during the Connect 360 PSP
Study periodApril 2018 to July 2019October 2019 to September 2021
PopulationPatients with severe eosinophilic asthma treated with benralizumabPatients with severe eosinophilic asthma treated with benralizumab
Definition of discontinuationDiscontinuation documented by the treating physician in the medical chartDefined as a gap of >9/>12 weeks since the last delivery date, with the date of benralizumab discontinuation defined as the last delivery date +9/+12 weeks and 1 day
Index dateFirst administration of benralizumabPSP enrolment date
Timepoint of assessment of discontinuation48 weeks since index date48 weeks since index date
  • BPAP, Benralizumab Patient Access Programme; ITC, indirect treatment comparison; PSP, patient support programme; UK, United Kingdom.